Bayer

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M

Retrieved on: 
Tuesday, February 13, 2024
Biotechnology, FDA, Professional Services, Other Health, Health, Pharmaceutical, Other Science, Research, Science, Clinical Trials, Finance, Therapy, Psoriasis, ALS, Inflammation, TPG, UPMC, Multiple sclerosis, Sudo, Series, DDF, Venture round, Bayer, Patient, TYK2, Investment, Partnership, Pharmaceutical industry

This brings the total raised in this upsized round to $147 million.

Key Points: 
  • This brings the total raised in this upsized round to $147 million.
  • With this second Series B round close, Sudo has raised a total of $188 million since its founding in 2020.
  • Specifically, we see scope to expand beyond MS into Alzheimer’s and ALS,” said Jonathan Behr, Partner, SV Health Investors.
  • Sudo is also developing a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.

Chagas Disease (T. cruzi Infection) Market: Comprehensive Global Analysis and Forecast Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Infectious Diseases, Pharmaceutical, Health, Pharmacy, Intelligence, Chagas disease, FDA, Infection, Epidemiology, ESG, Hospital, Health care, Bayer, Child, CDC, Movement, Trypanosoma cruzi, Research report, Nifurtimox, Vaccine

The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.

Key Points: 
  • The protozoan Trypanosoma cruzi is the cause of Chagas disease (CD), also known as American trypanosomiasis, a chronic, systemic, parasitic illness with substantial risk factors associated with low socioeconomic status.
  • It is widespread throughout 21 American countries, but it can spread to non-endemic nations worldwide through the movement of infected individuals.
  • The research report provides a thorough overview of the Chagas Disease market.
  • This report analyzes CD market trends with epidemiological and regional markets, highlights the current market and offers a detailed competitive environment analysis.

Phenovista Appoints Pharmaceutical Industry Veteran and Toxicology Expert Eckhard von Keutz, PhD to its Scientific Advisory Board

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Cell proliferation, Bayer, Workflow, Senior, Research fellow, Toxicology, Doctor of Philosophy, Liver, Cardiotoxicity, Management

Phenovista , a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board.

Key Points: 
  • Phenovista , a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board.
  • Most recently, Dr. von Keutz served as the Senior Vice President and Head of Translational Science (Preclinical and Early Clinical Development) at Bayer Pharmaceuticals.
  • “We are excited to welcome Eckhard to our Scientific Advisory Board,” said James Evans, PhD, Chief Executive Officer of Phenovista.
  • “Phenovista’s ability to support and de-risk mission-critical R&D decision-making is unmatched in the industry,” said Dr. von Keutz.

Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor

Retrieved on: 
Tuesday, February 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Multimedia, Pharmacokinetics, Growth, DSM-IV codes, DNA, Clinical trial, Therapy, Gene, Patient, Safety, STAT3, Executive Committee, Bayer, Disease, Acquisition, Cancer, Pharmaceutical industry

Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.

Key Points: 
  • Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced solid and hematologic tumors.
  • The start of the trial represents another major milestone for Vividion’s innovative chemoproteomics platform.
  • The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-130850 in patients with advanced solid and hematologic tumors as a single-agent and in combination with immune checkpoint inhibition.
  • “We are excited to announce the initiation and dosing of this highly selective STAT3 inhibitor,” said Jenna Goldberg, M.D., Chief Medical Officer of Vividion.

Pairwise Shares Advantages of Company-Developed Fulcrum™ Platform

Retrieved on: 
Thursday, February 1, 2024
Nature, USDA, Plant, Patent, RNA, Agriculture, Gene editing, Genetic variation, DNA, Genetics, Climate change, Food, Enzyme, SHARC, Allele, Bayer, IP, CRISPR, Breeding, Medicine, Organization

Durham, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pairwise , a technology company pioneering genetics-based innovation in food and agriculture, shares multiple recent advances in its Fulcrum™ Platform .

Key Points: 
  • Durham, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pairwise , a technology company pioneering genetics-based innovation in food and agriculture, shares multiple recent advances in its Fulcrum™ Platform .
  • Pairwise creates and uses advanced CRISPR-based tools like base editing and templated editing to create the desired level of genetic optimization,” said Ryan Bartlett, Pairwise Chief Technology Officer.
  • A complete suite of these novel technologies and proprietary tools for applying CRISPR technology make up the Fulcrum Platform, and enable Pairwise to unlock unique, commercially viable products with differentiated plant genetics.
  • As an important demonstration of the Pairwise Fulcrum Platform, the company introduced the first CRISPR-edited food to the food service channel and a retail test market in North America.

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.

Retrieved on: 
Wednesday, January 31, 2024
Partnership, ADS, CGM, History, HIV, Innovation system, Biomarker, Pain, Glucose meter, Dexcom, Trinity, World Health Organization, Trauma, Bayer, American depositary receipt, Acquisition, Base rate, EST, Health, Security (finance)

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.

Key Points: 
  • Waveform will no longer sell the Cascade device and the Company will not sell that device in its current form.
  • The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies.
  • Waveform is part of a portfolio company of Perceptive and the 9 million ADS being issued by the Company as partial consideration for the acquisition of the Waveform assets will be issued to Perceptive.
  • The Company will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Public, CGM, Diabetes, Patient, Glucose meter, Trinity, Physician, Bayer, Waveform, Acquisition, Letter, EST, Type 2 diabetes, Pharmaceutical industry

Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.

Key Points: 
  • Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
  • In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
  • To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
  • Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, January 30, 2024
Leo Pharma, Senior, CMO, Biomarker, Employment, Bayer, Drug development, CYCC, Medicine, Merck, Research and development, Hematology, University, Development, Merck & Co., Cyclacel, Pharmaceutical industry

will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.

Key Points: 
  • will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.
  • “We are delighted to have Brian join Cyclacel as CMO.
  • From June 2008 to 2020, he served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. in 2020.
  • Prior to ArQule, Dr. Schwartz was Chief Medical Officer at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma.

PittMoss Announces Appointment of Micki Seibel to Advisory Board

Retrieved on: 
Wednesday, January 31, 2024
Paper, Growth, Seibel, Agriculture, Digital transformation, Micki, Swarm Technologies, Temasek, Horticulture, Bayer, Farmer, Carnegie Mellon University, Woman, Organization

PITTSBURGH, Jan. 31, 2024 /PRNewswire/ -- PittMoss, manufacturer of revolutionary peat-free products made in America from organic, recycled paper and cardboard, today announces the appointment of Micki Seibel to the company's advisory board. 

Key Points: 
  • PITTSBURGH, Jan. 31, 2024 /PRNewswire/ -- PittMoss , manufacturer of revolutionary peat-free products made in America from organic, recycled paper and cardboard, today announces the appointment of Micki Seibel to the company's advisory board.
  • "On behalf of all of us at PittMoss, including our broad investor community, we are excited about Ms. Seibel joining our team," said Scott.
  • Previously, Seibel served as a member of the board of directors at Boost Biomes, a biotechnology company, which leverages microbiome data to create novel solutions for agriculture.
  • In 2021, Seibel – a graduate of Carnegie Mellon University – was named Digital Transformation Leader of the Year by Women in Tech Network.

FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate

Retrieved on: 
Tuesday, January 23, 2024
Patient, B cell, Therapy, Cell, IPSC, IRD, Paratriathlon, Partnership, Retina, IND, Human, AMD, Bayer, Peripheral vision, Pharmaceutical industry

an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.

Key Points: 
  • an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.
  • BlueRock Therapeutics, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, exercised its option to exclusively license OpCT-001, an iPSC-derived photoreceptor cell therapy for human retinal diseases.
  • Following the option exercise by BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics received an undisclosed license fee and are eligible to receive payments upon achievement of certain development and commercial milestones.
  • OpCT-001 is the first iPSC therapy candidate to be licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.